
381 articles by Jonathan Gardner
-
A play-by-play of the FDA meeting on J&J's one-shot coronavirus vaccine
Feb. 26, 2021 -
Moderna, Pfizer ready multi-pronged plans for coronavirus variants
Feb. 24, 2021 -
FDA review supports safety, efficacy of J&J coronavirus vaccine
Feb. 24, 2021 -
AstraZeneca withdraws immunotherapy in bladder cancer after trial failure
Feb. 22, 2021 -
Pfizer, BioNTech ask FDA approval to ease temperature requirements for coronavirus shot
Feb. 19, 2021 -
Novartis expects sales lift from expanded heart drug approval
Feb. 17, 2021 -
FDA approves Regeneron drug for rare genetic form of high cholesterol
Feb. 12, 2021 -
AstraZeneca plans for adapting vaccine to coronavirus variants, but offers longer timeline than rivals
Feb. 11, 2021 -
Small biotech gets big win on treatment for rare swelling disorder
Feb. 9, 2021 -
As COVID-19 becomes a business, vaccine makers confront thorny pricing questions
Feb. 9, 2021 -
PTC aims again for FDA review of Duchenne drug despite latest miss
Feb. 5, 2021 -
GSK expands CureVac vaccine partnership, changing course after setbacks
Feb. 3, 2021 -
Shifting strategy, Coherus buys rights to experimental cancer drug
Feb. 1, 2021 -
Novavax vaccine prevents COVID-19 in studies, but less effective against new variants
Jan. 28, 2021 -
Vaccine makers prepare response as coronavirus mutations raise alarms
Jan. 28, 2021 -
AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica
Jan. 25, 2021 -
Woodcock steps in as acting FDA chief with crucial vaccine decisions ahead
Jan. 21, 2021 -
Pfizer, BioNTech say vaccine effective against fast-spreading UK coronavirus variant
Jan. 20, 2021 -
Cancer-focused biotech turns its tools to building a 2nd-generation coronavirus vaccine
Jan. 19, 2021 -
Former FDA chief Kessler tapped as top Biden adviser for COVID-19 response
Jan. 15, 2021 -
5 questions facing the FDA in 2021
Jan. 14, 2021 -
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Jan. 12, 2021 -
JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
Jan. 11, 2021 -
Celgene's cell therapy spinout nets $292M from blank-check merger
Jan. 8, 2021 -
Sarepta gene therapy misses goal in key muscular dystrophy study
Jan. 7, 2021